Nautilus Biotechnology, Inc. Net Fee Amt
Nautilus Biotechnology, Inc. (NAUT) had Net Fee Amt of $0 as of 2026-09-11, per its S-3 filed 2026-09-11.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-11
- 2026-09-11: Net Fee Amt $0.00.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-11 | $0.00 S-3 · filed 2026-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |